Opinion|Videos|November 4, 2024
The Pathogenesis of CSU
Key Takeaways
- Autoimmune responses in CSU involve autoantibodies targeting IgE or FcεRI, leading to mast cell and basophil activation.
- BTK is a key mediator in mast cell degranulation, facilitating histamine release in CSU pathogenesis.
Panelists discuss how recent insights into chronic spontaneous urticaria (CSU) pathogenesis reveal potential autoimmune responses and highlight the role of Bruton tyrosine kinase (BTK) as a key mediator in mast cell degranulation and histamine release.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What have we learned about the possible mechanisms involved with CSU pathogenesis?
- Can you describe autoimmune responses and the role of Burton’s tyrosine kinase (or BTK) as a mediator in mast cell degranulation and histamine release?
Advertisement
Related to this article
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Bepirovirsen for Chronic Hepatitis B
2
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
5